199 related articles for article (PubMed ID: 16223057)
1. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Goldman D; Oroszi G; O'Malley S; Anton R
J Stud Alcohol Suppl; 2005 Jul; (15):56-64; discussion 33. PubMed ID: 16223057
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
3. Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
O'Brien CP
Curr Psychiatry Rep; 2008 Oct; 10(5):375-6. PubMed ID: 18803909
[No Abstract] [Full Text] [Related]
4. Pharmacogenetics of alcoholism: a clinical neuroscience perspective.
Ray LA; Courtney KE; Bujarski S; Squeglia LM
Pharmacogenomics; 2012 Jan; 13(2):129-32. PubMed ID: 22256863
[No Abstract] [Full Text] [Related]
5. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
6. Alcoholism: genes and mechanisms.
Oroszi G; Goldman D
Pharmacogenomics; 2004 Dec; 5(8):1037-48. PubMed ID: 15584875
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
8. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
Soyka M; Rösner S
Curr Drug Abuse Rev; 2008 Nov; 1(3):280-91. PubMed ID: 19630726
[TBL] [Abstract][Full Text] [Related]
9. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C; Kahler CW; Swift RM; O'Malley SS
J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
11. Combining treatments for alcoholism: why and how?
Mattson ME; Litten RZ
J Stud Alcohol Suppl; 2005 Jul; (15):8-16; discussion 6-7. PubMed ID: 16223051
[TBL] [Abstract][Full Text] [Related]
12. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
13. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
Johnson BA; Ait-Daoud N; Roache JD
J Stud Alcohol Suppl; 2005 Jul; (15):157-67; discussion 140. PubMed ID: 16223067
[TBL] [Abstract][Full Text] [Related]
14. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
Bouza C; Angeles M; Muñoz A; Amate JM
Addiction; 2004 Jul; 99(7):811-28. PubMed ID: 15200577
[TBL] [Abstract][Full Text] [Related]
16. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
17. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
18. The μ-opioid receptor and treatment response to naltrexone.
Thorsell A
Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
[TBL] [Abstract][Full Text] [Related]
19. [Acamprosate and naltrexone: similar efficacy for relapse].
Saitz R
Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
[No Abstract] [Full Text] [Related]
20. NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION.
Matošić A; Marušić S; Vidrih B; Kovak-Mufić A; Cicin-Šain L
Acta Clin Croat; 2016 Mar; 55(1):134-50. PubMed ID: 27333729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
